Post-earnings recap
Reported
Wed, Jul 29, 2026
EPS actual
$-1.08
EPS est.
$-0.74
EPS surprise
-46.14%
1-day move
-3.09%
Dyne Therapeutics reported a larger-than-expected loss per share, which contributed to a decline in the stock price by 3.09%. The lack of revenue and absence of guidance may raise concerns among investors about the company's future performance. Overall, the disappointing EPS result suggests challenges ahead for the company.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.08 | $-0.86 | -46.14% |
| Revenue | $0M | $0M | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options.
Last quarter
In Q1-2026, Dyne Therapeutics reported an EPS of $-0.73, slightly beating the estimate of $-0.74. The stock reacted positively, gaining 4.83% the following day.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-11.44%
Avg 1-day reaction
+1.97%
Analysts expect Dyne Therapeutics to report a loss this quarter, with a consensus EPS of $-0.86. The market is closely watching how the company manages its expenses and any updates on product development.
Bull case
If Dyne can demonstrate progress in its drug pipeline or provide positive updates on clinical trials, it could lead to a strong stock performance.
Bear case
Conversely, if the company misses EPS estimates or fails to provide clear guidance on future revenue, investor confidence may wane, leading to a decline in stock price.
Key metrics to watch
EPS
$-0.86Earnings per share (EPS) is a key indicator of the company's profitability and financial health.
Revenue
$0MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Dyne provide any updates on its drug pipeline or clinical trial results?
Investors are keen to know about progress in drug development, which could impact future revenue potential.
Q2
How does management plan to address the expected EPS loss this quarter?
Understanding management's strategy for cost management and revenue generation will be crucial for investor confidence.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.5%
Why consensus could be wrong
The Street may be overly pessimistic about Dyne's ability to manage costs, given its recent slight EPS beat and positive stock reaction.
Supporting evidence
Dyne has a history of beating EPS estimates, with a 63% beat rate over the last eight quarters.
The options market is pricing in a significant move, indicating that investors expect more volatility than has historically occurred.
Recent stock performance has shown resilience, suggesting that investors may be underestimating the company's potential.
Key risk
If Dyne's drug pipeline shows promising results, it could shift market sentiment significantly.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reflect the company's ability to manage costs and progress in its drug development efforts.
Bull confirmed if
A narrower EPS loss than the consensus estimate of $-0.86 could signal stronger operational performance.
Bear confirmed if
A wider EPS loss than expected could confirm concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±35.44%
Historical Avg
±6.2%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±35.4% while DYN has averaged ±6.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
60.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$40,000.00
2,500 sh
1 insider
Sold
$0.00
0 sh
0 insiders
Net
$40,000.00
Net buying
Most Active Insiders· 1 open-market trade
Smart-money positioning from the most recent 13F filings.
Institutional
103.69%
of float
Insider
0.24%
of float
Holders
334
institutions
Top Holders· as of Jun 2026
T. Rowe Price Investment Management, Inc.
30,912,287 sh · $493.7M
16.55%
0.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Dyne beats expectations and raises guidance, history suggests a potential stock increase of around 5.96% on the next trading day.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.
Miss
If Dyne misses EPS estimates, history suggests the stock could drop by about 9.27% the following day.
The lines on the call that would change the story.
$40,000.00
Net buying
Recent Transactions
Oct 2, 2026 · @ $16.00
2,500 sh
$40,000.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Blackrock Inc.
12,404,330 sh · $198.1M
6.64%
6.0%
Jupiter Topco LLC
11,997,738 sh · $191.6M
6.42%
100.0%
FMR, LLC
11,207,000 sh · $179.0M
6.00%
25.8%
State Street Corporation
7,458,263 sh · $119.1M
3.99%
12.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.